Lexapro (escitalopram) is a serotonin specific or selective serotonin reuptake inhibitor (SSRI) antidepressant used to treat depression. It is one of the most popular antidepressant medications and is also approved to treat other mental health conditions including obsessive compulsive disorder, bipolar disorder, and anxiety disorders.

Lexapro (escitalopram) is an antidepressant which works by increasing neurotransmitter activity in the brain.  It is an SSRI-type medication which only affects one type of neurotransmitter, serotonin.  It was designed to have fewer side effects, but it may also increase the risk of suicide in children and young adults and has been linked to a high risk of severe birth defects.

Forest Laboratories, Lexapro’s manufacturer has faced thousands of lawsuits after patients were harmed by the medication.

About Lexapro

Lexapro, the brand name of the generic escitalopram, is a serotonin-specific reuptake inhibitor (SSRI) antidepressant.  SSRIs are a newer type of antidepressant, which was designed to be more effective and have fewer side effects than older medications.  It is approved for major depression and generalized anxiety in adults and has been used for other psychiatric illnesses including bipolar disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD).

Neurotransmitters are chemicals, used by nerve cells to send messages to the next cell.  There are a number of these chemical messengers in the brain, including norepinephrine, dopamine and serotonin.  Depression may be caused by low neurotransmitter activity in the mood centers of the brain and increasing them can help relieve depression.

The first antidepressants worked by affecting both norepinephrine and serotonin but had debilitating side effects and were dangerous in certain conditions.  SSRI medications, which only affect serotonin, were designed to be more effective with fewer side effects.  Unfortunately, they have been found to cause a number of unexpected disorders, some of which may be fatal.

Lexapro’s manufacturer, Forest Laboratories was accused of improper marketing in 2009.  The company paid $313 million in fines for promoting unapproved uses, hiding negative clinical research results, and paying kickbacks to doctors.

Lexapro and Suicide

Lexapro may increase the risk for suicide in patients who are depressed.  Patients who are under 25 years of age, have bipolar disorder, or a history of suicidal thoughts, are at an even greater risk.   In 2004, the FDA began requiring that a “black box warning” be added to prescribing information for Lexapro which requires that information about the risk of suicide must be printed with a black border at the top of prescribing information for Lexapro.

Lexapro and Birth Defects

Lexapro and certain other SSRIs were initially considered much safer for pregnant patients because they had no effect on norepinephrine.  They were widely used in pregnancy until they were found to increase the risk of miscarriage and certain birth defects, some of which may be fatal.

In 2006, the FDA issued a warning about the risks of Lexapro-related birth defects and it is now classified as a Pregnancy Category C medication and should not be used during pregnancy unless absolutely necessary.

Birth defects linked to Lexapro use include:

  • Persistent Pulmonary Hypertension in Newborn (PPHN), fatal in 10% of infants
  • Hypoplastic Left/Right Heart Syndrome (HLHS, HRHS),
  • Anencephaly (born without part of brain, skull and scalp), usually fatal shortly after birth
  • Spina Bifida (underdeveloped vertebra which leaves spinal cord exposed), requires surgery, 15% fatal by age 4
  • Cleft Palate or Lip (missing portion of roof of mouth or upper front jaw), may require surgery
  • Omphalocele (abdominal organs on outside of body), requires surgery, sometimes fatal
  • Scoliosis (curved spine), may require surgery
  • Club feet (feet curl inwards, may require surgery
  • Autism Spectrum Disorder (ASD) or Delayed Development Disorder (DDD)
  • Withdrawal symptoms or Serotonin Syndrome in infants

Lexapro and Serotonin Syndrome

Lexapro use may cause “serotonin syndrome” which occurs when too much serotonin builds up in the brain.  It is more likely if it is taken other medications that also affect serotonin including treatments for migraine, cough suppressants, and certain herbal remedies.

Serotonin syndrome may include symptoms such as:

  • Unusually high fever
  • Increased heart rate and changes in rhythm
  • Loss of balance or coordination
  • Confusion and hallucinations
  • Seizures

In some cases, serotonin syndrome may be life-threatening.  All medications should be discussed with a physician to avoid drug interactions.

Lexapro withdrawal

Long-term use of Lexapro may lead to physical dependence in some patients.  If the medication is suddenly stopped, it may cause withdrawal symptoms known as “SSRI discontinuation syndrome”.

Some of these symptoms of serotonin withdrawal may last for a long time and may include:

  • Dizziness
  • Nausea/Diarrhea
  • Diarrhea
  • Headache
  • Chills and shivers
  • Brain “zaps”
  • Electrical type skin sensations

Tapering off of Lexapro, rather than simply stopping, may reduce the chance for severe withdrawal effects but some symptoms may last for a long period of time.

Side Effects of Lexapro

In addition to the serious risks of Lexapro, it also has a number of side effects which are related to serotonin.

Common side effects include:

  • Nausea
  • Diarrhea or constipation
  • Weight changes
  • Dizziness and drowsiness
  • Fatigue and/or insomnia
  • Sweating
  • Dry mouth
  • Headache
  • Sexual dysfunction (both males and females)

Forest Laboratories is facing a number of lawsuits for injuries caused by Lexapro use.  Patients or loved ones of those injured by Lexapro may be eligible for compensation for lost wages, medical costs and pain and suffering.

View Sources

  1. Carlat Psychiatry Report (2014) Lexapro: The Son of Celexa. Psych Central Professional. Accessed on 25 June 2014. http://pro.psychcentral.com/lexapro-the-son-of-celexa/001534.html
  2. Chambers, C.D., et al. (9 February 2006) Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn. New England Journal of Medicine. Accessed on 25 June 2014. http://www.nejm.org/doi/full/10.1056/NEJMoa052744
  3. Comer, B. (16 September 2012). Forest Labs to pay $313 Million in DOJ settlement. Medical Marketing & Media. Accessed on 25 June 2014. http://www.mmm-online.com/forest-labs-to-pay-313-million-in-doj-settlement/article/179029/
  4. Diiorio-Sterlin, C. (15 September 2010). U.S. Department of Justice Press Release: Drug Maker Forest Pleads Guilty: Will Pay More Than $313 Million to Resolve Criminal Charges and False Claims Act Allegations. Accessed on 25 June 2014. http://www.justice.gov/opa/pr/2010/September/10-civ-1028.html
  5. Food and Drug Administration. (2014). Lexapro (escitalopram oxalatate) Prescribing Information. Accessed on 25 June 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021323s032,021365s023lbl.pdf
  6. Forest Laboratories. (17 April 2010). Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2012 Earnings [Press release]. Accessed on 25 June 2014. http://news.frx.com/press-release/corporate-news/forest-laboratories-inc-reports-fiscal-year-fourth-quarter-2012-earning
  7. Fox News. (14 March 2012). FDA approves first generic version of depression drug Lexapro. Fox News. Accessed on 25 June 2014. http://www.foxnews.com/health/2012/03/14/fda-approves-first-generic-version-depression-drug-lexapro/
  8. Harris, G. (1 September 2009). Document Details Plan to Promote Costly Drug. The New York Times. Accessed on 25 June 2014. http://www.nytimes.com/2009/09/02/business/02drug.html?_r=0
  9. Holleran, K. (12 February 2012). Lexapro maker sued by women claiming children born with birth defects. The Madison Record. Accessed on 25 June 2014. http://madisonrecord.com/news/242029-lexapro-maker-sued-by-women-claiming-children-born-with-birth-defects
  10. Hostetter, A., Ritchie, J.C., Stowe, Z.N. (7 June 2007). Amniotic Fluid and Umbilical Cord Blood Concentrations of Antidepressants in Three Women. Biological Psychiatry. Accessed on 25 June 2014. http://www.biologicalpsychiatryjournal.com/article/S0006-3223%2800%2900958-6/abstract
  11. Louik, C., et al. (28 June 2007). First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects. New England Journal of Medicine. Accessed on 25 June 2014. http://www.nejm.org/doi/full/10.1056/NEJMoa067407
  12. Mayo Clinic (2014) Antidepressants: Safe during pregnancy?. Mayoclinic.org. Accessed on 25 June 2014. http://www.mayoclinic.org/healthy-living/pregnancy-week-by-week/in-depth/antidepressants/art-20046420
  13. Mayo Clinic. (2014) Serotonin Syndrome. Mayoclinic.org. Accessed 25 June 2014. http://www.mayoclinic.org/diseases-conditions/serotonin-syndrome/basics/definition/con-20028946
  14. NAMI (2014) Depression. Accessed 25 June 2014. National Institute of Mental Health. http://www.nimh.nih.gov/health/topics/depression/index.shtml
  15. NAMI (2014) Panic Disorder. Accessed 25 June 2014. National Institute of Mental Health. http://www.nimh.nih.gov/health/topics/panic-disorder/index.shtml
  16. Phys.org. ( 26 July 2006). Lexapro Lawsuit Filed Against Forest Labs. Phys. Accessed on 25 June 2014. http://phys.org/news73150784.html
  17. Pierson, R. (2009, March 20). Depression pill OK’d for kids but probe goes on. Reuters. Accessed on 25 June 2014. http://www.reuters.com/article/2009/03/20/forest-lexapro-idUSN2032438520090320
  18. RxList. (2014). Escitalopram Drug Interactions. RxList.com. Accessed on 25 June 2014 http://www.rxlist.com/drug-interactions/contraindicated-index/escitalopram-oral.htm
  19. US Senate. (12 August 2009). Lexapro Documents. Accessed on 25 June 2014. http://www.nytimes.com/packages/pdf/politics/20090831MEDICARE/20090831_MEDICARE.pdf
  20. Webb, G. (11 March 2009). Manufacturer of Lexapro – Forest Laboratories – Accused of Fraud. The Legal Examiner. Accessed on 25 June 2014. http://charlottesville.legalexaminer.com/fda-prescription-drugs/manufacturer-of-lexapro-forest-laboratories-accused-of-fraud/
  21. Weller, I.V.(December 2004) Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants. Accessed on 25 June 2014. http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019472.pdf
  22. Yost, P. (15 September 2010). Drug company to pay more than $313M over Celexa. Huffington Post. Accessed on 25 June 2014. http://www.huffingtonpost.com/huff-wires/20100915/us-doj-forest/